NCT01028053

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 365 (actual)
• Sponsor: GE Healthcare · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.

Conditions

• Mild Cognitive Impairment
• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	Flutemetamol (18F) Injection	All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.

Timeline

• Start date: 2009-12-01
• Primary completion: 2014-01-01
• Completion: 2014-01-01
• First posted: 2009-12-09
• Last updated: 2014-09-11
• Results posted: 2014-09-11

Locations

1 site across 1 country: United States